Bedinvetmab

Bedinvetmab, sold under the brand name Librela, is a fully canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Bedinvetmab, sold under the brand name Librela, is a fully canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. Librela is sponsored by Zoetis. Bedinvetmab was approved for medical use in the European Union in November 2020, and in the United States in May 2023. Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1338199829 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001338199829 · captured 2026-02-13 · ledger · version history

Cite this page as: encyclopegia.org, “Bedinvetmab”, snapshot enwiki-001338199829. https://encyclopegia.org/a/bedinvetmab

Sources cited in this revision

8 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.